CCEL

Business Context and Reporting Period

Company: Cryo-Cell International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: November 30, 2010
Business Overview: Cryo-Cell operates in one reportable segment focused on cellular processing and cryogenic storage. Its primary service is the collection and preservation of umbilical cord blood stem cells (U-Cord) for family use. The company also markets Célle, a service for storing menstrual stem cells, and Cryology RTS for reproductive tissue storage. As of November 30, 2010, the company and its global affiliates stored over 230,000 cord blood specimens worldwide.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income Surge: Net income increased by approximately 139% to $3.4 million. This increase was primarily driven by a non-cash reversal of approximately $1.8 million in the valuation allowance for deferred income taxes, based on the company's profitability in seven of the last eight quarters.
• Revenue Stability: Total revenue remained relatively flat, decreasing slightly by 0.1%. Processing and storage fees declined by 1% due to a 9% decrease in specimens processed, attributed to economic conditions and increased use of public cord blood banks. This was offset by a 14% increase in licensee income.
• Cost Savings: The company saved approximately $230,000 in cost of sales in 2010 after canceling a contract with Safti-Cell in late 2009 and moving all specimens to its own facility. This eliminated future storage fees estimated at $3.3 million over 12 years.
• Expense Increases: Marketing, general, and administrative expenses rose 6% to $9.5 million due to increased sales initiatives. Research and development expenses increased 30% to $133,000, focused on the Célle technology.

Guidance, Outlook, and Risks

• Outlook: Management anticipates funding future operations and capital expenditures (estimated at $750,000 over the next 12 months) with cash on hand and operating cash flows. The company expects to place greater promotional emphasis on the Célle service and increase marketing expenditures related to it.
• Strategic Acquisitions: The company retained an investment banking firm in August 2010 to explore potential strategic acquisition opportunities.
• Key Risks:
  • Economic Sensitivity: The business is susceptible to deteriorating economic conditions as stem cell storage is a discretionary purchase. The company has seen increased bad debt expense and relies on discounts to attract clients.
  • Market Acceptance: Success depends on the continued viability of cord blood stem cells and the market acceptance of new technologies like Célle, which requires scientific validation and regulatory approval.
  • Legal Proceedings: The company filed an action in December 2010 to enjoin the acquisition of its exclusive Mexican licensee (Cryo-Cell de Mexico) by a competitor, Cord Blood America, Inc. The court has directed that the transaction not close until further hearings.
  • International Licensing: A licensee in Germany (IMS) has not begun marketing due to regulatory issues and owes the company $50,000 in fees; collectability is uncertain.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the sustainability of the $1.8 million deferred tax valuation allowance reversal, as this was the primary driver of the 2010 net income increase.
• Specimen Volume Trends: Monitor the 9% decline in specimens processed to assess the impact of economic downturns and competition from public banks on future recurring revenue.
• Legal Outcome in Mexico: Track the litigation regarding the proposed acquisition of Cryo-Cell de Mexico, as this licensee generated approximately $837,000 in royalty income in 2010.
• German Licensee Status: Confirm the status of the German licensee (IMS) and the collectability of the $50,000 owed, given the regulatory hurdles cited.
• Revenue Sharing Agreements (RSAs): Review the long-term liability of $3.75 million associated with RSAs, which require the company to share a percentage of future storage revenues with investors in specific geographic areas.